3E0 Administration, Physiological Systems and Anatomical Regions, Introduction
3E00X05 Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach billable
3E00X0M Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach billable
3E00X28 Introduction of Oxazolidinones into Skin and Mucous Membranes, External Approach billable
3E00X29 Introduction of Other Anti-infective into Skin and Mucous Membranes, External Approach billable
3E00X3Z Introduction of Anti-inflammatory into Skin and Mucous Membranes, External Approach billable
3E00X4Z Introduction of Serum, Toxoid and Vaccine into Skin and Mucous Membranes, External Approach billable
3E00XBZ Introduction of Anesthetic Agent into Skin and Mucous Membranes, External Approach billable
3E00XGC Introduction of Other Therapeutic Substance into Skin and Mucous Membranes, External Approach billable
3E00XKZ Introduction of Other Diagnostic Substance into Skin and Mucous Membranes, External Approach billable
3E00XMZ Introduction of Pigment into Skin and Mucous Membranes, External Approach billable
3E00XNZ Introduction of Analgesics, Hypnotics, Sedatives into Skin and Mucous Membranes, External Approach billable
3E00XTZ Introduction of Destructive Agent into Skin and Mucous Membranes, External Approach billable
3E0102A Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Open Approach billable
3E01305 Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach billable
3E0130M Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach billable
3E01328 Introduction of Oxazolidinones into Subcutaneous Tissue, Percutaneous Approach billable
3E01329 Introduction of Other Anti-infective into Subcutaneous Tissue, Percutaneous Approach billable
3E0132A Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Percutaneous Approach billable
3E0133Z Introduction of Anti-inflammatory into Subcutaneous Tissue, Percutaneous Approach billable
3E01340 Introduction of Influenza Vaccine into Subcutaneous Tissue, Percutaneous Approach billable
3E0134Z Introduction of Serum, Toxoid and Vaccine into Subcutaneous Tissue, Percutaneous Approach billable
3E0136Z Introduction of Nutritional Substance into Subcutaneous Tissue, Percutaneous Approach billable
3E0137Z Introduction of Electrolytic and Water Balance Substance into Subcutaneous Tissue, Percutaneous Approach billable
3E013BZ Introduction of Anesthetic Agent into Subcutaneous Tissue, Percutaneous Approach billable
3E013GC Introduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach billable
3E013HZ Introduction of Radioactive Substance into Subcutaneous Tissue, Percutaneous Approach billable
3E013KZ Introduction of Other Diagnostic Substance into Subcutaneous Tissue, Percutaneous Approach billable
3E013NZ Introduction of Analgesics, Hypnotics, Sedatives into Subcutaneous Tissue, Percutaneous Approach billable
3E013TZ Introduction of Destructive Agent into Subcutaneous Tissue, Percutaneous Approach billable
3E013VG Introduction of Insulin into Subcutaneous Tissue, Percutaneous Approach billable
3E013VJ Introduction of Other Hormone into Subcutaneous Tissue, Percutaneous Approach billable
3E02305 Introduction of Other Antineoplastic into Muscle, Percutaneous Approach billable
3E0230M Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach billable
3E02328 Introduction of Oxazolidinones into Muscle, Percutaneous Approach billable
3E02329 Introduction of Other Anti-infective into Muscle, Percutaneous Approach billable
3E0233Z Introduction of Anti-inflammatory into Muscle, Percutaneous Approach billable
3E02340 Introduction of Influenza Vaccine into Muscle, Percutaneous Approach billable
3E0234Z Introduction of Serum, Toxoid and Vaccine into Muscle, Percutaneous Approach billable
3E0236Z Introduction of Nutritional Substance into Muscle, Percutaneous Approach billable
3E0237Z Introduction of Electrolytic and Water Balance Substance into Muscle, Percutaneous Approach billable
3E023BZ Introduction of Anesthetic Agent into Muscle, Percutaneous Approach billable
3E023GC Introduction of Other Therapeutic Substance into Muscle, Percutaneous Approach billable
3E023HZ Introduction of Radioactive Substance into Muscle, Percutaneous Approach billable
3E023KZ Introduction of Other Diagnostic Substance into Muscle, Percutaneous Approach billable
3E023NZ Introduction of Analgesics, Hypnotics, Sedatives into Muscle, Percutaneous Approach billable
3E023TZ Introduction of Destructive Agent into Muscle, Percutaneous Approach billable
3E03002 Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach billable
3E03003 Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach billable
3E03005 Introduction of Other Antineoplastic into Peripheral Vein, Open Approach billable
3E0300M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach billable
3E0300P Introduction of Clofarabine into Peripheral Vein, Open Approach billable
3E03016 Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Open billable
3E03017 Introduction of Other Thrombolytic into Peripheral Vein, Open Approach billable
3E03028 Introduction of Oxazolidinones into Peripheral Vein, Open Approach billable
3E03029 Introduction of Other Anti-infective into Peripheral Vein, Open Approach billable
3E0303Z Introduction of Anti-inflammatory into Peripheral Vein, Open Approach billable
3E0304Z Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Open Approach billable
3E0306Z Introduction of Nutritional Substance into Peripheral Vein, Open Approach billable
3E0307Z Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Open Approach billable
3E030FZ Introduction of Intracirculatory Anesthetic into Peripheral Vein, Open Approach billable
3E030GC Introduction of Other Therapeutic Substance into Peripheral Vein, Open Approach billable
3E030GN Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach billable
3E030HZ Introduction of Radioactive Substance into Peripheral Vein, Open Approach billable
3E030KZ Introduction of Other Diagnostic Substance into Peripheral Vein, Open Approach billable
3E030NZ Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Open Approach billable
3E030PZ Introduction of Platelet Inhibitor into Peripheral Vein, Open Approach billable
3E030RZ Introduction of Antiarrhythmic into Peripheral Vein, Open Approach billable
3E030TZ Introduction of Destructive Agent into Peripheral Vein, Open Approach billable
3E030U0 Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Open Approach billable
3E030U1 Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach billable
3E030VG Introduction of Insulin into Peripheral Vein, Open Approach billable
3E030VH Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Open Approach billable
3E030VJ Introduction of Other Hormone into Peripheral Vein, Open Approach billable
3E030WK Introduction of Immunostimulator into Peripheral Vein, Open billable
3E030WL Introduction of Immunosuppressive into Peripheral Vein, Open billable
3E030XZ Introduction of Vasopressor into Peripheral Vein, Open Approach billable
3E03302 Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach billable
3E03303 Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach billable
3E03305 Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach billable
3E0330M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach billable
3E0330P Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach billable
3E03316 Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Percutaneous billable
3E03317 Introduction of Other Thrombolytic into Peripheral Vein, Percutaneous Approach billable
3E03328 Introduction of Oxazolidinones into Peripheral Vein, Percutaneous Approach billable
3E03329 Introduction of Other Anti-infective into Peripheral Vein, Percutaneous Approach billable
3E0333Z Introduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach billable
3E0334Z Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Percutaneous Approach billable
3E0336Z Introduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach billable
3E0337Z Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Percutaneous Approach billable
3E033AZ Introduction of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach billable
3E033FZ Introduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach billable
3E033GC Introduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach billable
3E033GN Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Percutaneous Approach billable
3E033GQ Introduction of Glucarpidase into Peripheral Vein, Percutaneous Approach billable
3E033GR Introduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein, Percutaneous Approach billable
3E033HZ Introduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach billable
3E033KZ Introduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach billable
3E033NZ Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach billable
3E033PZ Introduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach billable
3E033RZ Introduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach billable
3E033TZ Introduction of Destructive Agent into Peripheral Vein, Percutaneous Approach billable
3E033U0 Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach billable
3E033U1 Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach billable
3E033VG Introduction of Insulin into Peripheral Vein, Percutaneous Approach billable
3E033VH Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Percutaneous Approach billable
3E033VJ Introduction of Other Hormone into Peripheral Vein, Percutaneous Approach billable
3E033WK Introduction of Immunostimulator into Peripheral Vein, Percutaneous billable
3E033WL Introduction of Immunosuppressive into Peripheral Vein, Percutaneous billable
3E033XZ Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach billable
3E04002 Introduction of High-dose Interleukin-2 into Central Vein, Open Approach billable
3E04003 Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach billable
3E04005 Introduction of Other Antineoplastic into Central Vein, Open Approach billable
3E0400M Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach billable
3E0400P Introduction of Clofarabine into Central Vein, Open Approach billable
3E04016 Introduction of Recombinant Human-activated Protein C into Central Vein, Open billable
3E04017 Introduction of Other Thrombolytic into Central Vein, Open Approach billable
3E04028 Introduction of Oxazolidinones into Central Vein, Open Approach billable
3E04029 Introduction of Other Anti-infective into Central Vein, Open Approach billable
3E0403Z Introduction of Anti-inflammatory into Central Vein, Open Approach billable
3E0404Z Introduction of Serum, Toxoid and Vaccine into Central Vein, Open Approach billable
3E0406Z Introduction of Nutritional Substance into Central Vein, Open Approach billable
3E0407Z Introduction of Electrolytic and Water Balance Substance into Central Vein, Open Approach billable
3E040FZ Introduction of Intracirculatory Anesthetic into Central Vein, Open Approach billable
3E040GC Introduction of Other Therapeutic Substance into Central Vein, Open Approach billable
3E040GN Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach billable
3E040HZ Introduction of Radioactive Substance into Central Vein, Open Approach billable
3E040KZ Introduction of Other Diagnostic Substance into Central Vein, Open Approach billable
3E040NZ Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Open Approach billable
3E040PZ Introduction of Platelet Inhibitor into Central Vein, Open Approach billable
3E040RZ Introduction of Antiarrhythmic into Central Vein, Open Approach billable
3E040TZ Introduction of Destructive Agent into Central Vein, Open Approach billable
3E040VG Introduction of Insulin into Central Vein, Open Approach billable
3E040VH Introduction of Human B-type Natriuretic Peptide into Central Vein, Open Approach billable
3E040VJ Introduction of Other Hormone into Central Vein, Open Approach billable
3E040WK Introduction of Immunostimulator into Central Vein, Open billable
3E040WL Introduction of Immunosuppressive into Central Vein, Open billable
3E040XZ Introduction of Vasopressor into Central Vein, Open Approach billable
3E04302 Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach billable
3E04303 Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach billable
3E04305 Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach billable
3E0430M Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach billable
3E0430P Introduction of Clofarabine into Central Vein, Percutaneous Approach billable
3E04316 Introduction of Recombinant Human-activated Protein C into Central Vein, Percutaneous billable
3E04317 Introduction of Other Thrombolytic into Central Vein, Percutaneous Approach billable
3E04328 Introduction of Oxazolidinones into Central Vein, Percutaneous Approach billable
3E04329 Introduction of Other Anti-infective into Central Vein, Percutaneous Approach billable
3E0433Z Introduction of Anti-inflammatory into Central Vein, Percutaneous Approach billable
3E0434Z Introduction of Serum, Toxoid and Vaccine into Central Vein, Percutaneous Approach billable
3E0436Z Introduction of Nutritional Substance into Central Vein, Percutaneous Approach billable
3E0437Z Introduction of Electrolytic and Water Balance Substance into Central Vein, Percutaneous Approach billable
3E043AZ Introduction of Embryonic Stem Cells into Central Vein, Percutaneous Approach billable
3E043FZ Introduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach billable
3E043GC Introduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach billable
3E043GN Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Percutaneous Approach billable
3E043GQ Introduction of Glucarpidase into Central Vein, Percutaneous Approach billable
3E043GR Introduction of Other Therapeutic Monoclonal Antibody into Central Vein, Percutaneous Approach billable
3E043HZ Introduction of Radioactive Substance into Central Vein, Percutaneous Approach billable
3E043KZ Introduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach billable
3E043NZ Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach billable
3E043PZ Introduction of Platelet Inhibitor into Central Vein, Percutaneous Approach billable
3E043RZ Introduction of Antiarrhythmic into Central Vein, Percutaneous Approach billable
3E043TZ Introduction of Destructive Agent into Central Vein, Percutaneous Approach billable
3E043VG Introduction of Insulin into Central Vein, Percutaneous Approach billable
3E043VH Introduction of Human B-type Natriuretic Peptide into Central Vein, Percutaneous Approach billable
3E043VJ Introduction of Other Hormone into Central Vein, Percutaneous Approach billable
3E043WK Introduction of Immunostimulator into Central Vein, Percutaneous billable
3E043WL Introduction of Immunosuppressive into Central Vein, Percutaneous billable
3E043XZ Introduction of Vasopressor into Central Vein, Percutaneous Approach billable
3E05002 Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach billable
3E05003 Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach billable
3E05005 Introduction of Other Antineoplastic into Peripheral Artery, Open Approach billable
3E0500M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach billable
3E0500P Introduction of Clofarabine into Peripheral Artery, Open Approach billable
3E05016 Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Open billable
3E05017 Introduction of Other Thrombolytic into Peripheral Artery, Open Approach billable
3E05028 Introduction of Oxazolidinones into Peripheral Artery, Open Approach billable
3E05029 Introduction of Other Anti-infective into Peripheral Artery, Open Approach billable
3E0503Z Introduction of Anti-inflammatory into Peripheral Artery, Open Approach billable
3E0504Z Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Open Approach billable
3E0506Z Introduction of Nutritional Substance into Peripheral Artery, Open Approach billable
3E0507Z Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Open Approach billable
3E050FZ Introduction of Intracirculatory Anesthetic into Peripheral Artery, Open Approach billable
3E050GC Introduction of Other Therapeutic Substance into Peripheral Artery, Open Approach billable
3E050GN Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach billable
3E050HZ Introduction of Radioactive Substance into Peripheral Artery, Open Approach billable
3E050KZ Introduction of Other Diagnostic Substance into Peripheral Artery, Open Approach billable
3E050NZ Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Open Approach billable
3E050PZ Introduction of Platelet Inhibitor into Peripheral Artery, Open Approach billable
3E050RZ Introduction of Antiarrhythmic into Peripheral Artery, Open Approach billable
3E050TZ Introduction of Destructive Agent into Peripheral Artery, Open Approach billable
3E050VG Introduction of Insulin into Peripheral Artery, Open Approach billable
3E050VH Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Open Approach billable
3E050VJ Introduction of Other Hormone into Peripheral Artery, Open Approach billable
3E050WK Introduction of Immunostimulator into Peripheral Artery, Open billable
3E050WL Introduction of Immunosuppressive into Peripheral Artery, Open billable
3E050XZ Introduction of Vasopressor into Peripheral Artery, Open Approach billable
3E05302 Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach billable
3E05303 Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach billable
3E05305 Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach billable
3E0530M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach billable
3E0530P Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach billable
3E05316 Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Percutaneous billable
3E05317 Introduction of Other Thrombolytic into Peripheral Artery, Percutaneous Approach billable
3E05328 Introduction of Oxazolidinones into Peripheral Artery, Percutaneous Approach billable
3E05329 Introduction of Other Anti-infective into Peripheral Artery, Percutaneous Approach billable
3E0533Z Introduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach billable
3E0534Z Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Percutaneous Approach billable
3E0536Z Introduction of Nutritional Substance into Peripheral Artery, Percutaneous Approach billable
3E0537Z Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Percutaneous Approach billable
3E053FZ Introduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach billable
3E053GC Introduction of Other Therapeutic Substance into Peripheral Artery, Percutaneous Approach billable
3E053GN Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Percutaneous Approach billable
3E053HZ Introduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach billable
3E053KZ Introduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach billable
3E053NZ Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Percutaneous Approach billable
3E053PZ Introduction of Platelet Inhibitor into Peripheral Artery, Percutaneous Approach billable
3E053RZ Introduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach billable
3E053TZ Introduction of Destructive Agent into Peripheral Artery, Percutaneous Approach billable
3E053VG Introduction of Insulin into Peripheral Artery, Percutaneous Approach billable
3E053VH Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Percutaneous Approach billable
3E053VJ Introduction of Other Hormone into Peripheral Artery, Percutaneous Approach billable
3E053WK Introduction of Immunostimulator into Peripheral Artery, Percutaneous billable
3E053WL Introduction of Immunosuppressive into Peripheral Artery, Percutaneous billable
3E053XZ Introduction of Vasopressor into Peripheral Artery, Percutaneous Approach billable
3E06002 Introduction of High-dose Interleukin-2 into Central Artery, Open Approach billable
3E06003 Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach billable
3E06005 Introduction of Other Antineoplastic into Central Artery, Open Approach billable
3E0600M Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach billable
3E0600P Introduction of Clofarabine into Central Artery, Open Approach billable
3E06016 Introduction of Recombinant Human-activated Protein C into Central Artery, Open billable
3E06017 Introduction of Other Thrombolytic into Central Artery, Open Approach billable
3E06028 Introduction of Oxazolidinones into Central Artery, Open Approach billable
3E06029 Introduction of Other Anti-infective into Central Artery, Open Approach billable
3E0603Z Introduction of Anti-inflammatory into Central Artery, Open Approach billable
3E0604Z Introduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach billable
3E0606Z Introduction of Nutritional Substance into Central Artery, Open Approach billable
3E0607Z Introduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach billable
3E060FZ Introduction of Intracirculatory Anesthetic into Central Artery, Open Approach billable
3E060GC Introduction of Other Therapeutic Substance into Central Artery, Open Approach billable
3E060GN Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach billable
3E060HZ Introduction of Radioactive Substance into Central Artery, Open Approach billable
3E060KZ Introduction of Other Diagnostic Substance into Central Artery, Open Approach billable
3E060NZ Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach billable
3E060PZ Introduction of Platelet Inhibitor into Central Artery, Open Approach billable
3E060RZ Introduction of Antiarrhythmic into Central Artery, Open Approach billable
3E060TZ Introduction of Destructive Agent into Central Artery, Open Approach billable
3E060VG Introduction of Insulin into Central Artery, Open Approach billable
3E060VH Introduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach billable
3E060VJ Introduction of Other Hormone into Central Artery, Open Approach billable
3E060WK Introduction of Immunostimulator into Central Artery, Open billable
3E060WL Introduction of Immunosuppressive into Central Artery, Open billable
3E060XZ Introduction of Vasopressor into Central Artery, Open Approach billable
3E06302 Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach billable
3E06303 Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach billable
3E06305 Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach billable
3E0630M Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach billable
3E0630P Introduction of Clofarabine into Central Artery, Percutaneous Approach billable
3E06316 Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous billable
3E06317 Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach billable
3E06328 Introduction of Oxazolidinones into Central Artery, Percutaneous Approach billable
3E06329 Introduction of Other Anti-infective into Central Artery, Percutaneous Approach billable
3E0633Z Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach billable
3E0634Z Introduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach billable
3E0636Z Introduction of Nutritional Substance into Central Artery, Percutaneous Approach billable
3E0637Z Introduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach billable
3E063FZ Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach billable
3E063GC Introduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach billable
3E063GN Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach billable
3E063HZ Introduction of Radioactive Substance into Central Artery, Percutaneous Approach billable
3E063KZ Introduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach billable
3E063NZ Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach billable
3E063PZ Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach billable
3E063RZ Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach billable
3E063TZ Introduction of Destructive Agent into Central Artery, Percutaneous Approach billable
3E063VG Introduction of Insulin into Central Artery, Percutaneous Approach billable
3E063VH Introduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach billable
3E063VJ Introduction of Other Hormone into Central Artery, Percutaneous Approach billable
3E063WK Introduction of Immunostimulator into Central Artery, Percutaneous billable
3E063WL Introduction of Immunosuppressive into Central Artery, Percutaneous billable
3E063XZ Introduction of Vasopressor into Central Artery, Percutaneous Approach billable
3E07016 Introduction of Recombinant Human-activated Protein C into Coronary Artery, Open billable
3E07017 Introduction of Other Thrombolytic into Coronary Artery, Open Approach billable
3E070GC Introduction of Other Therapeutic Substance into Coronary Artery, Open Approach billable
3E070KZ Introduction of Other Diagnostic Substance into Coronary Artery, Open Approach billable
3E070PZ Introduction of Platelet Inhibitor into Coronary Artery, Open Approach billable
3E07316 Introduction of Recombinant Human-activated Protein C into Coronary Artery, Percutaneous billable
3E07317 Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach billable
3E073GC Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Approach billable
3E073KZ Introduction of Other Diagnostic Substance into Coronary Artery, Percutaneous Approach billable
3E073PZ Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach billable
3E074GC Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Endoscopic Approach billable
3E08016 Introduction of Recombinant Human-activated Protein C into Heart, Open billable
3E08017 Introduction of Other Thrombolytic into Heart, Open Approach billable
3E080GC Introduction of Other Therapeutic Substance into Heart, Open Approach billable
3E080KZ Introduction of Other Diagnostic Substance into Heart, Open Approach billable
3E080PZ Introduction of Platelet Inhibitor into Heart, Open Approach billable
3E08316 Introduction of Recombinant Human-activated Protein C into Heart, Percutaneous billable
3E08317 Introduction of Other Thrombolytic into Heart, Percutaneous Approach billable
3E083GC Introduction of Other Therapeutic Substance into Heart, Percutaneous Approach billable
3E083KZ Introduction of Other Diagnostic Substance into Heart, Percutaneous Approach billable
3E083PZ Introduction of Platelet Inhibitor into Heart, Percutaneous Approach billable
3E084GC Introduction of Other Therapeutic Substance into Heart, Percutaneous Endoscopic Approach billable
3E09305 Introduction of Other Antineoplastic into Nose, Percutaneous Approach billable
3E0930M Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach billable
3E09328 Introduction of Oxazolidinones into Nose, Percutaneous Approach billable
3E09329 Introduction of Other Anti-infective into Nose, Percutaneous Approach billable
3E0933Z Introduction of Anti-inflammatory into Nose, Percutaneous Approach billable
3E0934Z Introduction of Serum, Toxoid and Vaccine into Nose, Percutaneous Approach billable
3E093BZ Introduction of Anesthetic Agent into Nose, Percutaneous Approach billable
3E093GC Introduction of Other Therapeutic Substance into Nose, Percutaneous Approach billable
3E093HZ Introduction of Radioactive Substance into Nose, Percutaneous Approach billable
3E093KZ Introduction of Other Diagnostic Substance into Nose, Percutaneous Approach billable
3E093NZ Introduction of Analgesics, Hypnotics, Sedatives into Nose, Percutaneous Approach billable
3E093TZ Introduction of Destructive Agent into Nose, Percutaneous Approach billable
3E09705 Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening billable
3E0970M Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening billable
3E09728 Introduction of Oxazolidinones into Nose, Via Natural or Artificial Opening billable
3E09729 Introduction of Other Anti-infective into Nose, Via Natural or Artificial Opening billable
3E0973Z Introduction of Anti-inflammatory into Nose, Via Natural or Artificial Opening billable
3E0974Z Introduction of Serum, Toxoid and Vaccine into Nose, Via Natural or Artificial Opening billable
3E097BZ Introduction of Anesthetic Agent into Nose, Via Natural or Artificial Opening billable
3E097GC Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening billable
3E097HZ Introduction of Radioactive Substance into Nose, Via Natural or Artificial Opening billable
3E097KZ Introduction of Other Diagnostic Substance into Nose, Via Natural or Artificial Opening billable
3E097NZ Introduction of Analgesics, Hypnotics, Sedatives into Nose, Via Natural or Artificial Opening billable
3E097TZ Introduction of Destructive Agent into Nose, Via Natural or Artificial Opening billable
3E09X05 Introduction of Other Antineoplastic into Nose, External Approach billable
3E09X0M Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach billable
3E09X28 Introduction of Oxazolidinones into Nose, External Approach billable
3E09X29 Introduction of Other Anti-infective into Nose, External Approach billable
3E09X3Z Introduction of Anti-inflammatory into Nose, External Approach billable
3E09X4Z Introduction of Serum, Toxoid and Vaccine into Nose, External Approach billable
3E09XBZ Introduction of Anesthetic Agent into Nose, External Approach billable
3E09XGC Introduction of Other Therapeutic Substance into Nose, External Approach billable
3E09XHZ Introduction of Radioactive Substance into Nose, External Approach billable
3E09XKZ Introduction of Other Diagnostic Substance into Nose, External Approach billable
3E09XNZ Introduction of Analgesics, Hypnotics, Sedatives into Nose, External Approach billable
3E09XTZ Introduction of Destructive Agent into Nose, External Approach billable
3E0A305 Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach billable
3E0A30M Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach billable
3E0A3GC Introduction of Other Therapeutic Substance into Bone Marrow, Percutaneous Approach billable
3E0B304 Introduction of Liquid Brachytherapy Radioisotope into Ear, Percutaneous Approach billable
3E0B305 Introduction of Other Antineoplastic into Ear, Percutaneous Approach billable
3E0B30M Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach billable
3E0B328 Introduction of Oxazolidinones into Ear, Percutaneous Approach billable
3E0B329 Introduction of Other Anti-infective into Ear, Percutaneous Approach billable
3E0B33Z Introduction of Anti-inflammatory into Ear, Percutaneous Approach billable
3E0B3BZ Introduction of Anesthetic Agent into Ear, Percutaneous Approach billable
3E0B3GC Introduction of Other Therapeutic Substance into Ear, Percutaneous Approach billable
3E0B3HZ Introduction of Radioactive Substance into Ear, Percutaneous Approach billable
3E0B3KZ Introduction of Other Diagnostic Substance into Ear, Percutaneous Approach billable
3E0B3NZ Introduction of Analgesics, Hypnotics, Sedatives into Ear, Percutaneous Approach billable
3E0B3TZ Introduction of Destructive Agent into Ear, Percutaneous Approach billable
3E0B704 Introduction of Liquid Brachytherapy Radioisotope into Ear, Via Natural or Artificial Opening billable
3E0B705 Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening billable
3E0B70M Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening billable
3E0B728 Introduction of Oxazolidinones into Ear, Via Natural or Artificial Opening billable
3E0B729 Introduction of Other Anti-infective into Ear, Via Natural or Artificial Opening billable
3E0B73Z Introduction of Anti-inflammatory into Ear, Via Natural or Artificial Opening billable
3E0B7BZ Introduction of Anesthetic Agent into Ear, Via Natural or Artificial Opening billable
3E0B7GC Introduction of Other Therapeutic Substance into Ear, Via Natural or Artificial Opening billable
3E0B7HZ Introduction of Radioactive Substance into Ear, Via Natural or Artificial Opening billable
3E0B7KZ Introduction of Other Diagnostic Substance into Ear, Via Natural or Artificial Opening billable
3E0B7NZ Introduction of Analgesics, Hypnotics, Sedatives into Ear, Via Natural or Artificial Opening billable
3E0B7TZ Introduction of Destructive Agent into Ear, Via Natural or Artificial Opening billable
3E0BX04 Introduction of Liquid Brachytherapy Radioisotope into Ear, External Approach billable
3E0BX05 Introduction of Other Antineoplastic into Ear, External Approach billable
3E0BX0M Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach billable
3E0BX28 Introduction of Oxazolidinones into Ear, External Approach billable
3E0BX29 Introduction of Other Anti-infective into Ear, External Approach billable
3E0BX3Z Introduction of Anti-inflammatory into Ear, External Approach billable
3E0BXBZ Introduction of Anesthetic Agent into Ear, External Approach billable
3E0BXGC Introduction of Other Therapeutic Substance into Ear, External Approach billable
3E0BXHZ Introduction of Radioactive Substance into Ear, External Approach billable
3E0BXKZ Introduction of Other Diagnostic Substance into Ear, External Approach billable
3E0BXNZ Introduction of Analgesics, Hypnotics, Sedatives into Ear, External Approach billable
3E0BXTZ Introduction of Destructive Agent into Ear, External Approach billable
3E0C304 Introduction of Liquid Brachytherapy Radioisotope into Eye, Percutaneous Approach billable
3E0C305 Introduction of Other Antineoplastic into Eye, Percutaneous Approach billable
3E0C30M Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach billable
3E0C328 Introduction of Oxazolidinones into Eye, Percutaneous Approach billable
3E0C329 Introduction of Other Anti-infective into Eye, Percutaneous Approach billable
3E0C33Z Introduction of Anti-inflammatory into Eye, Percutaneous Approach billable
3E0C3BZ Introduction of Anesthetic Agent into Eye, Percutaneous Approach billable
3E0C3GC Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach billable
3E0C3HZ Introduction of Radioactive Substance into Eye, Percutaneous Approach billable
3E0C3KZ Introduction of Other Diagnostic Substance into Eye, Percutaneous Approach billable
3E0C3MZ Introduction of Pigment into Eye, Percutaneous Approach billable
3E0C3NZ Introduction of Analgesics, Hypnotics, Sedatives into Eye, Percutaneous Approach billable
3E0C3SF Introduction of Other Gas into Eye, Percutaneous Approach billable
3E0C3TZ Introduction of Destructive Agent into Eye, Percutaneous Approach billable
3E0C704 Introduction of Liquid Brachytherapy Radioisotope into Eye, Via Natural or Artificial Opening billable
3E0C705 Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening billable
3E0C70M Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening billable
3E0C728 Introduction of Oxazolidinones into Eye, Via Natural or Artificial Opening billable
3E0C729 Introduction of Other Anti-infective into Eye, Via Natural or Artificial Opening billable
3E0C73Z Introduction of Anti-inflammatory into Eye, Via Natural or Artificial Opening billable
3E0C7BZ Introduction of Anesthetic Agent into Eye, Via Natural or Artificial Opening billable
3E0C7GC Introduction of Other Therapeutic Substance into Eye, Via Natural or Artificial Opening billable
3E0C7HZ Introduction of Radioactive Substance into Eye, Via Natural or Artificial Opening billable
3E0C7KZ Introduction of Other Diagnostic Substance into Eye, Via Natural or Artificial Opening billable
3E0C7MZ Introduction of Pigment into Eye, Via Natural or Artificial Opening billable
3E0C7NZ Introduction of Analgesics, Hypnotics, Sedatives into Eye, Via Natural or Artificial Opening billable
3E0C7SF Introduction of Other Gas into Eye, Via Natural or Artificial Opening billable
3E0C7TZ Introduction of Destructive Agent into Eye, Via Natural or Artificial Opening billable
3E0CX04 Introduction of Liquid Brachytherapy Radioisotope into Eye, External Approach billable
3E0CX05 Introduction of Other Antineoplastic into Eye, External Approach billable
3E0CX0M Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach billable
3E0CX28 Introduction of Oxazolidinones into Eye, External Approach billable
3E0CX29 Introduction of Other Anti-infective into Eye, External Approach billable
3E0CX3Z Introduction of Anti-inflammatory into Eye, External Approach billable
3E0CXBZ Introduction of Anesthetic Agent into Eye, External Approach billable
3E0CXGC Introduction of Other Therapeutic Substance into Eye, External Approach billable
3E0CXHZ Introduction of Radioactive Substance into Eye, External Approach billable
3E0CXKZ Introduction of Other Diagnostic Substance into Eye, External Approach billable
3E0CXMZ Introduction of Pigment into Eye, External Approach billable
3E0CXNZ Introduction of Analgesics, Hypnotics, Sedatives into Eye, External Approach billable
3E0CXSF Introduction of Other Gas into Eye, External Approach billable
3E0CXTZ Introduction of Destructive Agent into Eye, External Approach billable
3E0D304 Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Percutaneous Approach billable
3E0D305 Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach billable
3E0D30M Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach billable
3E0D328 Introduction of Oxazolidinones into Mouth and Pharynx, Percutaneous Approach billable
3E0D329 Introduction of Other Anti-infective into Mouth and Pharynx, Percutaneous Approach billable
3E0D33Z Introduction of Anti-inflammatory into Mouth and Pharynx, Percutaneous Approach billable
3E0D34Z Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Percutaneous Approach billable
3E0D36Z Introduction of Nutritional Substance into Mouth and Pharynx, Percutaneous Approach billable
3E0D37Z Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Percutaneous Approach billable
3E0D3BZ Introduction of Anesthetic Agent into Mouth and Pharynx, Percutaneous Approach billable
3E0D3GC Introduction of Other Therapeutic Substance into Mouth and Pharynx, Percutaneous Approach billable
3E0D3HZ Introduction of Radioactive Substance into Mouth and Pharynx, Percutaneous Approach billable
3E0D3KZ Introduction of Other Diagnostic Substance into Mouth and Pharynx, Percutaneous Approach billable
3E0D3NZ Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Percutaneous Approach billable
3E0D3RZ Introduction of Antiarrhythmic into Mouth and Pharynx, Percutaneous Approach billable
3E0D3TZ Introduction of Destructive Agent into Mouth and Pharynx, Percutaneous Approach billable
3E0D704 Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D705 Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D70M Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D728 Introduction of Oxazolidinones into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D729 Introduction of Other Anti-infective into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D73Z Introduction of Anti-inflammatory into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D74Z Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D76Z Introduction of Nutritional Substance into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D77Z Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D7BZ Introduction of Anesthetic Agent into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D7GC Introduction of Other Therapeutic Substance into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D7HZ Introduction of Radioactive Substance into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D7KZ Introduction of Other Diagnostic Substance into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D7NZ Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D7RZ Introduction of Antiarrhythmic into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0D7TZ Introduction of Destructive Agent into Mouth and Pharynx, Via Natural or Artificial Opening billable
3E0DX04 Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, External Approach billable
3E0DX05 Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach billable
3E0DX0M Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach billable
3E0DX28 Introduction of Oxazolidinones into Mouth and Pharynx, External Approach billable
3E0DX29 Introduction of Other Anti-infective into Mouth and Pharynx, External Approach billable
3E0DX3Z Introduction of Anti-inflammatory into Mouth and Pharynx, External Approach billable
3E0DX4Z Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, External Approach billable
3E0DX6Z Introduction of Nutritional Substance into Mouth and Pharynx, External Approach billable
3E0DX7Z Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, External Approach billable
3E0DXBZ Introduction of Anesthetic Agent into Mouth and Pharynx, External Approach billable
3E0DXGC Introduction of Other Therapeutic Substance into Mouth and Pharynx, External Approach billable
3E0DXHZ Introduction of Radioactive Substance into Mouth and Pharynx, External Approach billable
3E0DXKZ Introduction of Other Diagnostic Substance into Mouth and Pharynx, External Approach billable
3E0DXNZ Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, External Approach billable
3E0DXRZ Introduction of Antiarrhythmic into Mouth and Pharynx, External Approach billable
3E0DXTZ Introduction of Destructive Agent into Mouth and Pharynx, External Approach billable
3E0E304 Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Percutaneous Approach billable
3E0E305 Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach billable
3E0E30M Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach billable
3E0E328 Introduction of Oxazolidinones into Products of Conception, Percutaneous Approach billable
3E0E329 Introduction of Other Anti-infective into Products of Conception, Percutaneous Approach billable
3E0E33Z Introduction of Anti-inflammatory into Products of Conception, Percutaneous Approach billable
3E0E36Z Introduction of Nutritional Substance into Products of Conception, Percutaneous Approach billable
3E0E37Z Introduction of Electrolytic and Water Balance Substance into Products of Conception, Percutaneous Approach billable
3E0E3BZ Introduction of Anesthetic Agent into Products of Conception, Percutaneous Approach billable
3E0E3GC Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Approach billable
3E0E3HZ Introduction of Radioactive Substance into Products of Conception, Percutaneous Approach billable
3E0E3KZ Introduction of Other Diagnostic Substance into Products of Conception, Percutaneous Approach billable
3E0E3NZ Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Percutaneous Approach billable
3E0E3SF Introduction of Other Gas into Products of Conception, Percutaneous Approach billable
3E0E3TZ Introduction of Destructive Agent into Products of Conception, Percutaneous Approach billable
3E0E4GC Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Endoscopic Approach billable
3E0E704 Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening billable
3E0E705 Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening billable
3E0E70M Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening billable
3E0E728 Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening billable
3E0E729 Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening billable
3E0E73Z Introduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening billable
3E0E76Z Introduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening billable
3E0E77Z Introduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening billable
3E0E7BZ Introduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening billable
3E0E7GC Introduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening billable
3E0E7HZ Introduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening billable
3E0E7KZ Introduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening billable
3E0E7NZ Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening billable
3E0E7SF Introduction of Other Gas into Products of Conception, Via Natural or Artificial Opening billable
3E0E7TZ Introduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening billable
3E0E804 Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E805 Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E80M Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E828 Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E829 Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E83Z Introduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E86Z Introduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E87Z Introduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E8BZ Introduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E8GC Introduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E8HZ Introduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E8KZ Introduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E8NZ Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E8SF Introduction of Other Gas into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0E8TZ Introduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic billable
3E0F304 Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Percutaneous Approach billable
3E0F305 Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach billable
3E0F30M Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach billable
3E0F328 Introduction of Oxazolidinones into Respiratory Tract, Percutaneous Approach billable
3E0F329 Introduction of Other Anti-infective into Respiratory Tract, Percutaneous Approach billable
3E0F33Z Introduction of Anti-inflammatory into Respiratory Tract, Percutaneous Approach billable
3E0F36Z Introduction of Nutritional Substance into Respiratory Tract, Percutaneous Approach billable
3E0F37Z Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Percutaneous Approach billable
3E0F3BZ Introduction of Anesthetic Agent into Respiratory Tract, Percutaneous Approach billable
3E0F3GC Introduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Approach billable
3E0F3HZ Introduction of Radioactive Substance into Respiratory Tract, Percutaneous Approach billable
3E0F3KZ Introduction of Other Diagnostic Substance into Respiratory Tract, Percutaneous Approach billable
3E0F3NZ Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Percutaneous Approach billable
3E0F3SD Introduction of Nitric Oxide Gas into Respiratory Tract, Percutaneous Approach billable
3E0F3SF Introduction of Other Gas into Respiratory Tract, Percutaneous Approach billable
3E0F3TZ Introduction of Destructive Agent into Respiratory Tract, Percutaneous Approach billable
3E0F4GC Introduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Endoscopic Approach billable
3E0F704 Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F705 Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F70M Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F728 Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F729 Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F73Z Introduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F76Z Introduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F77Z Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F7BZ Introduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F7GC Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F7HZ Introduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F7KZ Introduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F7NZ Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F7SD Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F7SF Introduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F7TZ Introduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening billable
3E0F804 Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F805 Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F80M Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F828 Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F829 Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F83Z Introduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F86Z Introduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F87Z Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F8BZ Introduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F8GC Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F8HZ Introduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F8KZ Introduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F8NZ Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F8SD Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F8SF Introduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0F8TZ Introduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic billable
3E0G304 Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Percutaneous Approach billable
3E0G305 Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach billable
3E0G30M Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach billable
3E0G328 Introduction of Oxazolidinones into Upper GI, Percutaneous Approach billable
3E0G329 Introduction of Other Anti-infective into Upper GI, Percutaneous Approach billable
3E0G33Z Introduction of Anti-inflammatory into Upper GI, Percutaneous Approach billable
3E0G36Z Introduction of Nutritional Substance into Upper GI, Percutaneous Approach billable
3E0G37Z Introduction of Electrolytic and Water Balance Substance into Upper GI, Percutaneous Approach billable
3E0G3BZ Introduction of Anesthetic Agent into Upper GI, Percutaneous Approach billable
3E0G3GC Introduction of Other Therapeutic Substance into Upper GI, Percutaneous Approach billable
3E0G3HZ Introduction of Radioactive Substance into Upper GI, Percutaneous Approach billable
3E0G3KZ Introduction of Other Diagnostic Substance into Upper GI, Percutaneous Approach billable
3E0G3NZ Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Percutaneous Approach billable
3E0G3SF Introduction of Other Gas into Upper GI, Percutaneous Approach billable
3E0G3TZ Introduction of Destructive Agent into Upper GI, Percutaneous Approach billable
3E0G4GC Introduction of Other Therapeutic Substance into Upper GI, Percutaneous Endoscopic Approach billable
3E0G704 Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening billable
3E0G705 Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening billable
3E0G70M Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening billable
3E0G728 Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening billable
3E0G729 Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening billable
3E0G73Z Introduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening billable
3E0G76Z Introduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening billable
3E0G77Z Introduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening billable
3E0G7BZ Introduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening billable
3E0G7GC Introduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening billable
3E0G7HZ Introduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening billable
3E0G7KZ Introduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening billable
3E0G7NZ Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening billable
3E0G7SF Introduction of Other Gas into Upper GI, Via Natural or Artificial Opening billable
3E0G7TZ Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening billable
3E0G804 Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G805 Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G80M Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G828 Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G829 Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G83Z Introduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G86Z Introduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G87Z Introduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G8BZ Introduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G8GC Introduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G8HZ Introduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G8KZ Introduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G8NZ Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G8SF Introduction of Other Gas into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0G8TZ Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening Endoscopic billable
3E0H304 Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Percutaneous Approach billable
3E0H305 Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach billable
3E0H30M Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach billable
3E0H328 Introduction of Oxazolidinones into Lower GI, Percutaneous Approach billable
3E0H329 Introduction of Other Anti-infective into Lower GI, Percutaneous Approach billable
3E0H33Z Introduction of Anti-inflammatory into Lower GI, Percutaneous Approach billable
3E0H36Z Introduction of Nutritional Substance into Lower GI, Percutaneous Approach billable
3E0H37Z Introduction of Electrolytic and Water Balance Substance into Lower GI, Percutaneous Approach billable
3E0H3BZ Introduction of Anesthetic Agent into Lower GI, Percutaneous Approach billable
3E0H3GC Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Approach billable
3E0H3HZ Introduction of Radioactive Substance into Lower GI, Percutaneous Approach billable
3E0H3KZ Introduction of Other Diagnostic Substance into Lower GI, Percutaneous Approach billable
3E0H3NZ Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Percutaneous Approach billable
3E0H3SF Introduction of Other Gas into Lower GI, Percutaneous Approach billable
3E0H3TZ Introduction of Destructive Agent into Lower GI, Percutaneous Approach billable
3E0H4GC Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Endoscopic Approach billable
3E0H704 Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening billable
3E0H705 Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening billable
3E0H70M Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening billable
3E0H728 Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening billable
3E0H729 Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening billable
3E0H73Z Introduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening billable
3E0H76Z Introduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening billable
3E0H77Z Introduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening billable
3E0H7BZ Introduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening billable
3E0H7GC Introduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening billable
3E0H7HZ Introduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening billable
3E0H7KZ Introduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening billable
3E0H7NZ Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening billable
3E0H7SF Introduction of Other Gas into Lower GI, Via Natural or Artificial Opening billable
3E0H7TZ Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening billable
3E0H804 Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H805 Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H80M Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H828 Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H829 Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H83Z Introduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H86Z Introduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H87Z Introduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H8BZ Introduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H8GC Introduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H8HZ Introduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H8KZ Introduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H8NZ Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H8SF Introduction of Other Gas into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0H8TZ Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening Endoscopic billable
3E0J304 Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J305 Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J30M Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J328 Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J329 Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J33Z Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J36Z Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J37Z Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J3BZ Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J3GC Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J3HZ Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J3KZ Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J3NZ Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J3SF Introduction of Other Gas into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J3TZ Introduction of Destructive Agent into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J3U0 Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J3U1 Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach billable
3E0J4GC Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Endoscopic Approach billable
3E0J704 Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J705 Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J70M Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J728 Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J729 Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J73Z Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J76Z Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J77Z Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J7BZ Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J7GC Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J7HZ Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J7KZ Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J7NZ Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J7SF Introduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J7TZ Introduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J7U0 Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J7U1 Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening billable
3E0J804 Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J805 Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J80M Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J828 Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J829 Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J83Z Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J86Z Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J87Z Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J8BZ Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J8GC Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J8HZ Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J8KZ Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J8NZ Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J8SF Introduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J8TZ Introduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J8U0 Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0J8U1 Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K304 Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Percutaneous Approach billable
3E0K305 Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach billable
3E0K30M Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach billable
3E0K328 Introduction of Oxazolidinones into Genitourinary Tract, Percutaneous Approach billable
3E0K329 Introduction of Other Anti-infective into Genitourinary Tract, Percutaneous Approach billable
3E0K33Z Introduction of Anti-inflammatory into Genitourinary Tract, Percutaneous Approach billable
3E0K36Z Introduction of Nutritional Substance into Genitourinary Tract, Percutaneous Approach billable
3E0K37Z Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Percutaneous Approach billable
3E0K3BZ Introduction of Anesthetic Agent into Genitourinary Tract, Percutaneous Approach billable
3E0K3GC Introduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Approach billable
3E0K3HZ Introduction of Radioactive Substance into Genitourinary Tract, Percutaneous Approach billable
3E0K3KZ Introduction of Other Diagnostic Substance into Genitourinary Tract, Percutaneous Approach billable
3E0K3NZ Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Percutaneous Approach billable
3E0K3SF Introduction of Other Gas into Genitourinary Tract, Percutaneous Approach billable
3E0K3TZ Introduction of Destructive Agent into Genitourinary Tract, Percutaneous Approach billable
3E0K4GC Introduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Endoscopic Approach billable
3E0K704 Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K705 Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K70M Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K728 Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K729 Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K73Z Introduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K76Z Introduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K77Z Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K7BZ Introduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K7GC Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K7HZ Introduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K7KZ Introduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K7NZ Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K7SF Introduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K7TZ Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening billable
3E0K804 Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K805 Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K80M Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K828 Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K829 Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K83Z Introduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K86Z Introduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K87Z Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K8BZ Introduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K8GC Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K8HZ Introduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K8KZ Introduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K8NZ Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K8SF Introduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0K8TZ Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic billable
3E0L05Z Introduction of Adhesion Barrier into Pleural Cavity, Open Approach billable
3E0L304 Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Percutaneous Approach billable
3E0L305 Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach billable
3E0L30M Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach billable
3E0L317 Introduction of Other Thrombolytic into Pleural Cavity, Percutaneous Approach billable
3E0L328 Introduction of Oxazolidinones into Pleural Cavity, Percutaneous Approach billable
3E0L329 Introduction of Other Anti-infective into Pleural Cavity, Percutaneous Approach billable
3E0L33Z Introduction of Anti-inflammatory into Pleural Cavity, Percutaneous Approach billable
3E0L35Z Introduction of Adhesion Barrier into Pleural Cavity, Percutaneous Approach billable
3E0L36Z Introduction of Nutritional Substance into Pleural Cavity, Percutaneous Approach billable
3E0L37Z Introduction of Electrolytic and Water Balance Substance into Pleural Cavity, Percutaneous Approach billable
3E0L3BZ Introduction of Anesthetic Agent into Pleural Cavity, Percutaneous Approach billable
3E0L3GC Introduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Approach billable
3E0L3HZ Introduction of Radioactive Substance into Pleural Cavity, Percutaneous Approach billable
3E0L3KZ Introduction of Other Diagnostic Substance into Pleural Cavity, Percutaneous Approach billable
3E0L3NZ Introduction of Analgesics, Hypnotics, Sedatives into Pleural Cavity, Percutaneous Approach billable
3E0L3SF Introduction of Other Gas into Pleural Cavity, Percutaneous Approach billable
3E0L3TZ Introduction of Destructive Agent into Pleural Cavity, Percutaneous Approach billable
3E0L45Z Introduction of Adhesion Barrier into Pleural Cavity, Percutaneous Endoscopic Approach billable
3E0L4GC Introduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Endoscopic Approach billable
3E0L704 Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Via Natural or Artificial Opening billable
3E0L705 Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening billable
3E0L70M Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening billable
3E0L7SF Introduction of Other Gas into Pleural Cavity, Via Natural or Artificial Opening billable
3E0M05Z Introduction of Adhesion Barrier into Peritoneal Cavity, Open Approach billable
3E0M304 Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Percutaneous Approach billable
3E0M305 Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach billable
3E0M30M Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach billable
3E0M30Y Introduction of Hyperthermic Antineoplastic into Peritoneal Cavity, Percutaneous Approach billable
3E0M328 Introduction of Oxazolidinones into Peritoneal Cavity, Percutaneous Approach billable
3E0M329 Introduction of Other Anti-infective into Peritoneal Cavity, Percutaneous Approach billable
3E0M33Z Introduction of Anti-inflammatory into Peritoneal Cavity, Percutaneous Approach billable
3E0M35Z Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Approach billable
3E0M36Z Introduction of Nutritional Substance into Peritoneal Cavity, Percutaneous Approach billable
3E0M37Z Introduction of Electrolytic and Water Balance Substance into Peritoneal Cavity, Percutaneous Approach billable
3E0M3BZ Introduction of Anesthetic Agent into Peritoneal Cavity, Percutaneous Approach billable
3E0M3GC Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Approach billable
3E0M3HZ Introduction of Radioactive Substance into Peritoneal Cavity, Percutaneous Approach billable
3E0M3KZ Introduction of Other Diagnostic Substance into Peritoneal Cavity, Percutaneous Approach billable
3E0M3NZ Introduction of Analgesics, Hypnotics, Sedatives into Peritoneal Cavity, Percutaneous Approach billable
3E0M3SF Introduction of Other Gas into Peritoneal Cavity, Percutaneous Approach billable
3E0M3TZ Introduction of Destructive Agent into Peritoneal Cavity, Percutaneous Approach billable
3E0M45Z Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Endoscopic Approach billable
3E0M4GC Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Endoscopic Approach billable
3E0M704 Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Via Natural or Artificial Opening billable
3E0M705 Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening billable
3E0M70M Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening billable
3E0M7SF Introduction of Other Gas into Peritoneal Cavity, Via Natural or Artificial Opening billable
3E0N304 Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Percutaneous Approach billable
3E0N305 Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach billable
3E0N30M Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach billable
3E0N328 Introduction of Oxazolidinones into Male Reproductive, Percutaneous Approach billable
3E0N329 Introduction of Other Anti-infective into Male Reproductive, Percutaneous Approach billable
3E0N33Z Introduction of Anti-inflammatory into Male Reproductive, Percutaneous Approach billable
3E0N36Z Introduction of Nutritional Substance into Male Reproductive, Percutaneous Approach billable
3E0N37Z Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Percutaneous Approach billable
3E0N3BZ Introduction of Anesthetic Agent into Male Reproductive, Percutaneous Approach billable
3E0N3GC Introduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Approach billable
3E0N3HZ Introduction of Radioactive Substance into Male Reproductive, Percutaneous Approach billable
3E0N3KZ Introduction of Other Diagnostic Substance into Male Reproductive, Percutaneous Approach billable
3E0N3NZ Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Percutaneous Approach billable
3E0N3SF Introduction of Other Gas into Male Reproductive, Percutaneous Approach billable
3E0N3TZ Introduction of Destructive Agent into Male Reproductive, Percutaneous Approach billable
3E0N4GC Introduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Endoscopic Approach billable
3E0N704 Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening billable
3E0N705 Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening billable
3E0N70M Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening billable
3E0N728 Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening billable
3E0N729 Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening billable
3E0N73Z Introduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening billable
3E0N76Z Introduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening billable
3E0N77Z Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening billable
3E0N7BZ Introduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening billable
3E0N7GC Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening billable
3E0N7HZ Introduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening billable
3E0N7KZ Introduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening billable
3E0N7NZ Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening billable
3E0N7SF Introduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening billable
3E0N7TZ Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening billable
3E0N804 Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N805 Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N80M Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N828 Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N829 Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N83Z Introduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N86Z Introduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N87Z Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N8BZ Introduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N8GC Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N8HZ Introduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N8KZ Introduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N8NZ Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N8SF Introduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0N8TZ Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P05Z Introduction of Adhesion Barrier into Female Reproductive, Open Approach billable
3E0P304 Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Percutaneous Approach billable
3E0P305 Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach billable
3E0P30M Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach billable
3E0P328 Introduction of Oxazolidinones into Female Reproductive, Percutaneous Approach billable
3E0P329 Introduction of Other Anti-infective into Female Reproductive, Percutaneous Approach billable
3E0P33Z Introduction of Anti-inflammatory into Female Reproductive, Percutaneous Approach billable
3E0P35Z Introduction of Adhesion Barrier into Female Reproductive, Percutaneous Approach billable
3E0P36Z Introduction of Nutritional Substance into Female Reproductive, Percutaneous Approach billable
3E0P37Z Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Percutaneous Approach billable
3E0P3BZ Introduction of Anesthetic Agent into Female Reproductive, Percutaneous Approach billable
3E0P3GC Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Approach billable
3E0P3HZ Introduction of Radioactive Substance into Female Reproductive, Percutaneous Approach billable
3E0P3KZ Introduction of Other Diagnostic Substance into Female Reproductive, Percutaneous Approach billable
3E0P3LZ Introduction of Sperm into Female Reproductive, Percutaneous Approach billable
3E0P3NZ Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Percutaneous Approach billable
3E0P3Q0 Introduction of Autologous Fertilized Ovum into Female Reproductive, Percutaneous Approach billable
3E0P3Q1 Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Percutaneous Approach billable
3E0P3SF Introduction of Other Gas into Female Reproductive, Percutaneous Approach billable
3E0P3TZ Introduction of Destructive Agent into Female Reproductive, Percutaneous Approach billable
3E0P3VZ Introduction of Hormone into Female Reproductive, Percutaneous Approach billable
3E0P45Z Introduction of Adhesion Barrier into Female Reproductive, Percutaneous Endoscopic Approach billable
3E0P4GC Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Endoscopic Approach billable
3E0P704 Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening billable
3E0P705 Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening billable
3E0P70M Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening billable
3E0P728 Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening billable
3E0P729 Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening billable
3E0P73Z Introduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening billable
3E0P76Z Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening billable
3E0P77Z Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7BZ Introduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7GC Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7HZ Introduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7KZ Introduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7LZ Introduction of Sperm into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7NZ Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7Q0 Introduction of Autologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7Q1 Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7SF Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7TZ Introduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening billable
3E0P7VZ Introduction of Hormone into Female Reproductive, Via Natural or Artificial Opening billable
3E0P804 Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P805 Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P80M Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P828 Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P829 Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P83Z Introduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P86Z Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P87Z Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P8BZ Introduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P8GC Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P8HZ Introduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P8KZ Introduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P8NZ Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P8SF Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0P8TZ Introduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic billable
3E0Q004 Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Open Approach billable
3E0Q005 Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach billable
3E0Q00M Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach billable
3E0Q028 Introduction of Oxazolidinones into Cranial Cavity and Brain, Open Approach billable
3E0Q029 Introduction of Other Anti-infective into Cranial Cavity and Brain, Open Approach billable
3E0Q03Z Introduction of Anti-inflammatory into Cranial Cavity and Brain, Open Approach billable
3E0Q06Z Introduction of Nutritional Substance into Cranial Cavity and Brain, Open Approach billable
3E0Q07Z Introduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Open Approach billable
3E0Q0AZ Introduction of Embryonic Stem Cells into Cranial Cavity and Brain, Open Approach billable
3E0Q0BZ Introduction of Anesthetic Agent into Cranial Cavity and Brain, Open Approach billable
3E0Q0E0 Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach billable
3E0Q0E1 Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach billable
3E0Q0GC Introduction of Other Therapeutic Substance into Cranial Cavity and Brain, Open Approach billable
3E0Q0HZ Introduction of Radioactive Substance into Cranial Cavity and Brain, Open Approach billable
3E0Q0KZ Introduction of Other Diagnostic Substance into Cranial Cavity and Brain, Open Approach billable
3E0Q0NZ Introduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Open Approach billable
3E0Q0SF Introduction of Other Gas into Cranial Cavity and Brain, Open Approach billable
3E0Q0TZ Introduction of Destructive Agent into Cranial Cavity and Brain, Open Approach billable
3E0Q304 Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q305 Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q30M Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q328 Introduction of Oxazolidinones into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q329 Introduction of Other Anti-infective into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q33Z Introduction of Anti-inflammatory into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q36Z Introduction of Nutritional Substance into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q37Z Introduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3AZ Introduction of Embryonic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3BZ Introduction of Anesthetic Agent into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3E0 Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3E1 Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3GC Introduction of Other Therapeutic Substance into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3HZ Introduction of Radioactive Substance into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3KZ Introduction of Other Diagnostic Substance into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3NZ Introduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3SF Introduction of Other Gas into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q3TZ Introduction of Destructive Agent into Cranial Cavity and Brain, Percutaneous Approach billable
3E0Q704 Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Via Natural or Artificial Opening billable
3E0Q705 Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening billable
3E0Q70M Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening billable
3E0Q7SF Introduction of Other Gas into Cranial Cavity and Brain, Via Natural or Artificial Opening billable
3E0R0AZ Introduction of Embryonic Stem Cells into Spinal Canal, Open Approach billable
3E0R0E0 Introduction of Autologous Somatic Stem Cells into Spinal Canal, Open Approach billable
3E0R0E1 Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Open Approach billable
3E0R302 Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach billable
3E0R303 Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach billable
3E0R304 Introduction of Liquid Brachytherapy Radioisotope into Spinal Canal, Percutaneous Approach billable
3E0R305 Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach billable
3E0R30M Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach billable
3E0R328 Introduction of Oxazolidinones into Spinal Canal, Percutaneous Approach billable
3E0R329 Introduction of Other Anti-infective into Spinal Canal, Percutaneous Approach billable
3E0R33Z Introduction of Anti-inflammatory into Spinal Canal, Percutaneous Approach billable
3E0R36Z Introduction of Nutritional Substance into Spinal Canal, Percutaneous Approach billable
3E0R37Z Introduction of Electrolytic and Water Balance Substance into Spinal Canal, Percutaneous Approach billable
3E0R3AZ Introduction of Embryonic Stem Cells into Spinal Canal, Percutaneous Approach billable
3E0R3BZ Introduction of Anesthetic Agent into Spinal Canal, Percutaneous Approach billable
3E0R3E0 Introduction of Autologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach billable
3E0R3E1 Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach billable
3E0R3GC Introduction of Other Therapeutic Substance into Spinal Canal, Percutaneous Approach billable
3E0R3HZ Introduction of Radioactive Substance into Spinal Canal, Percutaneous Approach billable
3E0R3KZ Introduction of Other Diagnostic Substance into Spinal Canal, Percutaneous Approach billable
3E0R3NZ Introduction of Analgesics, Hypnotics, Sedatives into Spinal Canal, Percutaneous Approach billable
3E0R3SF Introduction of Other Gas into Spinal Canal, Percutaneous Approach billable
3E0R3TZ Introduction of Destructive Agent into Spinal Canal, Percutaneous Approach billable
3E0R7SF Introduction of Other Gas into Spinal Canal, Via Natural or Artificial Opening billable
3E0S302 Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach billable
3E0S303 Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach billable
3E0S304 Introduction of Liquid Brachytherapy Radioisotope into Epidural Space, Percutaneous Approach billable
3E0S305 Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach billable
3E0S30M Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach billable
3E0S328 Introduction of Oxazolidinones into Epidural Space, Percutaneous Approach billable
3E0S329 Introduction of Other Anti-infective into Epidural Space, Percutaneous Approach billable
3E0S33Z Introduction of Anti-inflammatory into Epidural Space, Percutaneous Approach billable
3E0S36Z Introduction of Nutritional Substance into Epidural Space, Percutaneous Approach billable
3E0S37Z Introduction of Electrolytic and Water Balance Substance into Epidural Space, Percutaneous Approach billable
3E0S3BZ Introduction of Anesthetic Agent into Epidural Space, Percutaneous Approach billable
3E0S3GC Introduction of Other Therapeutic Substance into Epidural Space, Percutaneous Approach billable
3E0S3HZ Introduction of Radioactive Substance into Epidural Space, Percutaneous Approach billable
3E0S3KZ Introduction of Other Diagnostic Substance into Epidural Space, Percutaneous Approach billable
3E0S3NZ Introduction of Analgesics, Hypnotics, Sedatives into Epidural Space, Percutaneous Approach billable
3E0S3SF Introduction of Other Gas into Epidural Space, Percutaneous Approach billable
3E0S3TZ Introduction of Destructive Agent into Epidural Space, Percutaneous Approach billable
3E0S7SF Introduction of Other Gas into Epidural Space, Via Natural or Artificial Opening billable
3E0T33Z Introduction of Anti-inflammatory into Peripheral Nerves and Plexi, Percutaneous Approach billable
3E0T3BZ Introduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach billable
3E0T3GC Introduction of Other Therapeutic Substance into Peripheral Nerves and Plexi, Percutaneous Approach billable
3E0T3TZ Introduction of Destructive Agent into Peripheral Nerves and Plexi, Percutaneous Approach billable
3E0U028 Introduction of Oxazolidinones into Joints, Open Approach billable
3E0U029 Introduction of Other Anti-infective into Joints, Open Approach billable
3E0U0GB Introduction of Recombinant Bone Morphogenetic Protein into Joints, Open Approach billable
3E0U0GC Introduction of Other Therapeutic Substance into Joints, Open Approach billable
3E0U304 Introduction of Liquid Brachytherapy Radioisotope into Joints, Percutaneous Approach billable
3E0U305 Introduction of Other Antineoplastic into Joints, Percutaneous Approach billable
3E0U30M Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach billable
3E0U328 Introduction of Oxazolidinones into Joints, Percutaneous Approach billable
3E0U329 Introduction of Other Anti-infective into Joints, Percutaneous Approach billable
3E0U33Z Introduction of Anti-inflammatory into Joints, Percutaneous Approach billable
3E0U36Z Introduction of Nutritional Substance into Joints, Percutaneous Approach billable
3E0U37Z Introduction of Electrolytic and Water Balance Substance into Joints, Percutaneous Approach billable
3E0U3BZ Introduction of Anesthetic Agent into Joints, Percutaneous Approach billable
3E0U3GB Introduction of Recombinant Bone Morphogenetic Protein into Joints, Percutaneous Approach billable
3E0U3GC Introduction of Other Therapeutic Substance into Joints, Percutaneous Approach billable
3E0U3HZ Introduction of Radioactive Substance into Joints, Percutaneous Approach billable
3E0U3KZ Introduction of Other Diagnostic Substance into Joints, Percutaneous Approach billable
3E0U3NZ Introduction of Analgesics, Hypnotics, Sedatives into Joints, Percutaneous Approach billable
3E0U3SF Introduction of Other Gas into Joints, Percutaneous Approach billable
3E0U3TZ Introduction of Destructive Agent into Joints, Percutaneous Approach billable
3E0U4GC Introduction of Other Therapeutic Substance into Joints, Percutaneous Endoscopic Approach billable
3E0V0GB Introduction of Recombinant Bone Morphogenetic Protein into Bones, Open Approach billable
3E0V0GC Introduction of Other Therapeutic Substance into Bones, Open Approach billable
3E0V305 Introduction of Other Antineoplastic into Bones, Percutaneous Approach billable
3E0V30M Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach billable
3E0V328 Introduction of Oxazolidinones into Bones, Percutaneous Approach billable
3E0V329 Introduction of Other Anti-infective into Bones, Percutaneous Approach billable
3E0V33Z Introduction of Anti-inflammatory into Bones, Percutaneous Approach billable
3E0V36Z Introduction of Nutritional Substance into Bones, Percutaneous Approach billable
3E0V37Z Introduction of Electrolytic and Water Balance Substance into Bones, Percutaneous Approach billable
3E0V3BZ Introduction of Anesthetic Agent into Bones, Percutaneous Approach billable
3E0V3GB Introduction of Recombinant Bone Morphogenetic Protein into Bones, Percutaneous Approach billable
3E0V3GC Introduction of Other Therapeutic Substance into Bones, Percutaneous Approach billable
3E0V3HZ Introduction of Radioactive Substance into Bones, Percutaneous Approach billable
3E0V3KZ Introduction of Other Diagnostic Substance into Bones, Percutaneous Approach billable
3E0V3NZ Introduction of Analgesics, Hypnotics, Sedatives into Bones, Percutaneous Approach billable
3E0V3TZ Introduction of Destructive Agent into Bones, Percutaneous Approach billable
3E0V4GC Introduction of Other Therapeutic Substance into Bones, Percutaneous Endoscopic Approach billable
3E0W305 Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach billable
3E0W30M Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach billable
3E0W328 Introduction of Oxazolidinones into Lymphatics, Percutaneous Approach billable
3E0W329 Introduction of Other Anti-infective into Lymphatics, Percutaneous Approach billable
3E0W33Z Introduction of Anti-inflammatory into Lymphatics, Percutaneous Approach billable
3E0W36Z Introduction of Nutritional Substance into Lymphatics, Percutaneous Approach billable
3E0W37Z Introduction of Electrolytic and Water Balance Substance into Lymphatics, Percutaneous Approach billable
3E0W3BZ Introduction of Anesthetic Agent into Lymphatics, Percutaneous Approach billable
3E0W3GC Introduction of Other Therapeutic Substance into Lymphatics, Percutaneous Approach billable
3E0W3HZ Introduction of Radioactive Substance into Lymphatics, Percutaneous Approach billable
3E0W3KZ Introduction of Other Diagnostic Substance into Lymphatics, Percutaneous Approach billable
3E0W3NZ Introduction of Analgesics, Hypnotics, Sedatives into Lymphatics, Percutaneous Approach billable
3E0W3TZ Introduction of Destructive Agent into Lymphatics, Percutaneous Approach billable
3E0X33Z Introduction of Anti-inflammatory into Cranial Nerves, Percutaneous Approach billable
3E0X3BZ Introduction of Anesthetic Agent into Cranial Nerves, Percutaneous Approach billable
3E0X3GC Introduction of Other Therapeutic Substance into Cranial Nerves, Percutaneous Approach billable
3E0X3TZ Introduction of Destructive Agent into Cranial Nerves, Percutaneous Approach billable
3E0Y304 Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Percutaneous Approach billable
3E0Y305 Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach billable
3E0Y30M Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach billable
3E0Y328 Introduction of Oxazolidinones into Pericardial Cavity, Percutaneous Approach billable
3E0Y329 Introduction of Other Anti-infective into Pericardial Cavity, Percutaneous Approach billable
3E0Y33Z Introduction of Anti-inflammatory into Pericardial Cavity, Percutaneous Approach billable
3E0Y36Z Introduction of Nutritional Substance into Pericardial Cavity, Percutaneous Approach billable
3E0Y37Z Introduction of Electrolytic and Water Balance Substance into Pericardial Cavity, Percutaneous Approach billable
3E0Y3BZ Introduction of Anesthetic Agent into Pericardial Cavity, Percutaneous Approach billable
3E0Y3GC Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Approach billable
3E0Y3HZ Introduction of Radioactive Substance into Pericardial Cavity, Percutaneous Approach billable
3E0Y3KZ Introduction of Other Diagnostic Substance into Pericardial Cavity, Percutaneous Approach billable
3E0Y3NZ Introduction of Analgesics, Hypnotics, Sedatives into Pericardial Cavity, Percutaneous Approach billable
3E0Y3SF Introduction of Other Gas into Pericardial Cavity, Percutaneous Approach billable
3E0Y3TZ Introduction of Destructive Agent into Pericardial Cavity, Percutaneous Approach billable
3E0Y4GC Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Endoscopic Approach billable
3E0Y704 Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Via Natural or Artificial Opening billable
3E0Y705 Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening billable
3E0Y70M Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening billable
3E0Y7SF Introduction of Other Gas into Pericardial Cavity, Via Natural or Artificial Opening billable